T22296 |
Cisapride hydrate
|
260779-88-2
|
98%
|
|
Cisapride acts directly as a selective agonist of serotonin 5-HT4 receptor with IC50 value of 0.483 μM. And It also acts indirectly as a parasympathomimetic.
|
T4485 |
Lazertinib
|
1903008-80-9
|
99.96%
|
|
Lazertinib (GNS-1480) is an effective, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790...
|
T2303 |
(S)-Afatinib
|
439081-18-2
|
99.96%
|
|
(S)-Afatinib (BIBW2992) is an irreversible EGFR family inhibitor with IC50s of 0.5/0.4/10/14/1 nM for EGFRwt, EGFR (L858R), EGFR (L858R/T790M), HER2, and HER4, r...
|
T2364 |
Tucatinib
|
937263-43-9
|
99.96%
|
|
Tucatinib (ONT-380) is a potent and selective HER2 inhibitor (IC50: 8 nM).
|
T19814 |
CP-380736
|
179688-29-0
|
99.91%
|
|
CP-380736 (PF-00520893) is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a tyrosine kinase that activates MAPK, JNK, and Akt pathways, and is an ...
|
T1144L |
Lidocaine Hydrochloride hydrate
|
6108-05-0
|
99.91%
|
|
Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property.
|
T2491 |
AZ-5104
|
1421373-98-9
|
99.9%
|
|
AZ5104 is a potent EGFR inhibitor.
|
T0373 |
Erlotinib
|
183321-74-6
|
99.89%
|
|
Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
|
T22954 |
LY 456236 hydrochloride
|
338736-46-2
|
99.89%
|
|
LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM. LY456236 has selective, non-competitive and oral activ...
|
T3558 |
EBE-A22
|
229476-53-3
|
99.88%
|
|
EBE-A22 (PD153035 Analog 63) is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.
|
T6124 |
Mubritinib
|
366017-09-6
|
99.87%
|
|
Mubritinib (TAK-165) (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM.
|
T2894 |
Norcantharidin
|
5442-12-6
|
99.86%
|
|
Norcantharidin (Norcantharadine) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
|
T10419 |
AV-412
|
451493-31-5
|
99.85%
|
|
AV-412 (MP412) is an EGFR inhibitor (EGFR, EGFR T790M, EGFR L858R, EGFR L858R/T790M and ErbB2 with IC50s of 0.75, 0.79, 0.5, 2.3, 19 nM).
|
T13619 |
Cloperastine fendizoate
|
85187-37-7
|
99.85%
|
|
Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).
|
T34656 |
SKLB 1028
|
1350544-93-2
|
99.85%
|
|
SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and con...
|
T5462 |
Almonertinib
|
1899921-05-1
|
99.85%
|
|
Almonertinib (HS-10296) is an inhibitor of EGFR activation mutation and tolerant mutation of EGFR T790M, which has only limited activity against wild-type EGFR.
|
T6908 |
NSC 228155
|
113104-25-9
|
99.84%
|
|
NSC 228155 is an activator of EGFR, binding to the sEGFR dimerization domain II and modulate EGFR tyrosine phosphorylation.
|
T2106 |
WS6
|
1421227-53-3
|
99.83%
|
|
WS6, a β cell proliferation inducer, regulates Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
|
T6196 |
PP1
|
172889-26-8
|
99.82%
|
|
PP1 (AGL 1872), a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
|
T15621 |
Rilematovir
|
1383450-81-4
|
99.82%
|
|
Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncyt...
|